AA
ALNY icon

ALPS Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

ALPS Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$464K Buy
+1,542
New +$465K ﹤0.01% 1009
2017
Q2 		– Sell
-73,998
Closed -$3.79M – 769
2017
Q1 		$3.79M Sell
73,998
-8,470
-10% -$391K 0.03% 151
2016
Q4 		$3.09M Buy
+82,468
New +$3.45M 0.02% 155

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's ALNY Position: Q2 2026 in Review

ALPS Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 1,542 shares worth $464K. The stake represents ﹤0.01% of the portfolio and ranks #1009 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in ALNY as recently as Q1 2017.

ALPS Advisors first reported a position in ALNY in Q4 2016 and has held it in 3 quarters since. The position peaked at $3.79M in Q1 2017. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • ALPS Advisors held 1,542 shares of Alnylam Pharmaceuticals worth $464K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new ALPS Advisors position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1009 holding.
  • ALPS Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 3 quarters since.
  • ALPS Advisors's Alnylam Pharmaceuticals position peaked at $3.79M in Q1 2017.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.